Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast Cancer
NCT05192798Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Jan 2022
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib, bevacizumab in triple-negative breast cancer (TNBC), sponsored by First Affiliated Hospital of Bengbu Medical University. Started Jan 2022; status: recruiting.
02
Drugs
Rivoceranibbevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05192798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05192798.